Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study
Circulation: Cardiovascular Imaging · 2024
DOI: 10.1161/circimaging.123.016206 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Imaging, 2024. Verfasst von Leopoldo Pérez de Isla und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Clinico San Carlos University Hospital, Madrid, Spain (L.P.d.I.). Hauptthemen laut MEDLINE: Coronary Artery Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Plaque, Atherosclerotic, Hypercholesterolemia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Intensive lipid-lowering therapy may induce coronary atherosclerosis regression. Nevertheless, the factors underlying the effect of lipid-lowering therapy on disease regression remain poorly characterized. Our aim was to determine which characteristics of atherosclerotic plaque are associated with a greater reduction in coronary plaque burden (PB) after treatment with alirocumab in patients with familial hypercholesterolemia. METHODS: The ARCHITECT study (Effect of Alirocumab on Atherosclerotic Plaque Volume, Architecture and Composition) is a phase IV, open-label, multicenter, single-arm clinical trial to assess the effect of the treatment with alirocumab for 78 weeks on the coronary atherosclerotic PB and its characteristics in subjects with familial hypercholesterolemia without clinical atherosclerotic cardiovascular disease. Participants underwent a coronary computed tomographic angiography at baseline and a final one at 78 weeks. Every patient received alirocumab 150 mg subcutaneously every 14 days in addition to high-intensity statin therapy. RESULTS: One hundred and four patients were enrolled. Median age was 53.3 (46.2–59.4) years and 54 were women (51.9%). The global coronary PB changed from 34.6% (32.5%–36.8%) at entry to 30.4% (27.4%–33.4%) at follow-up, which is −4.6% (−7.7% to −1.9%; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Department, Clinico San Carlos University Hospital, Madrid, Spain (L.P.d.I.).
- Internal Medicine Department, Hospital Abente y Lago, A Coruña, Spain (J.L.D.-D.).
- Internal Medicine Department, Hospital Infanta Elena, Huelva, Spain (M.J.R.).
- Internal Medicine Department, Hospital Virgen del Rocío, Sevilla, Spain (O.M.-G.).
- Internal Medicine Department, Hospital Universitario Virgen de las Nieves, Granada, Spain (J.D.M.).
- Endocrinology Department, Hospital Universitario Lucus Augusti, Lugo, Spain (R.A.).
ORCID-Profile: Leopoldo Pérez de Isla, Jose L Díaz-Díaz, Manuel J Romero, Ovidio Muñiz-Grijalvo, Juan D Mediavilla, Rosa Argüeso, Raimundo de Andrés, Francisco Fuentes, Juan F Sánchez Muñoz-Torrero, Patricia Rubio, Lorena Suárez Gutierrez
Zitieren
APA
Pérez de Isla, L., Díaz-Díaz, J. L., Romero, M. J., Muñiz-Grijalvo, O., Mediavilla, J. D., Argüeso, R., de Andrés, R., Fuentes, F., Sánchez Muñoz-Torrero, J. F., Rubio, P., Álvarez-Baños, P., Mañas, D., Suárez Gutierrez, L., Saltijeral Cerezo, A., Mata, P., & SAFEHEART Investigators (2024). Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study. Circulation: Cardiovascular Imaging. https://doi.org/10.1161/circimaging.123.016206
Vancouver
Pérez de Isla L, Díaz-Díaz JL, Romero MJ, Muñiz-Grijalvo O, Mediavilla JD, Argüeso R, et al. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study. Circulation: Cardiovascular Imaging. 2024. doi:10.1161/circimaging.123.016206
BibTeX
@article{PrezdeIsla2024,
author = {Pérez de Isla, Leopoldo and Díaz-Díaz, Jose L and Romero, Manuel J and Muñiz-Grijalvo, Ovidio and Mediavilla, Juan D and Argüeso, Rosa and de Andrés, Raimundo and Fuentes, Francisco and Sánchez Muñoz-Torrero, Juan F and Rubio, Patricia and Álvarez-Baños, Pilar and Mañas, Dolores and Suárez Gutierrez, Lorena and Saltijeral Cerezo, Adriana and Mata, Pedro and SAFEHEART Investigators, SAFEHEART Investigators},
title = {Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study},
journal = {Circulation: Cardiovascular Imaging},
year = {2024},
doi = {10.1161/circimaging.123.016206}
}
EUVIMED